Multiple Myeloma Clinical Trials (April 2026): 564 Recruiting Interventional Studies

Last updated: April 21, 2026

Current Clinical Trial Landscape

Recruiting Trials by Treatment Setting

Newly Diagnosed — Transplant-Eligible

Induction, transplant, and maintenance trials:

• • NCT04566328 - Testing combination therapy (quadruplet) in newly diagnosed myeloma (Phase 3)
  • NCT03937635 - Lenalidomide + dex ± daratumumab in transplant-eligible patients (Phase 3)
  • NCT05827016 - Iberdomide (CELMoD) maintenance vs lenalidomide maintenance post-transplant (Phase 3)

Newly Diagnosed — Transplant-Ineligible

Testing bispecifics and CELMoDs in first-line for older/unfit patients:

• • NCT05623020 - Elranatamab + daratumumab + lenalidomide + dex in transplant-ineligible (Phase 3)
  • NCT06182774 - Fixed duration vs continuous anti-CD38 therapy in transplant-ineligible (Phase 3)
  • NCT06152575 - MagnetisMM-32: Elranatamab in newly diagnosed myeloma (Phase 3)

Relapsed / Refractory — Early Relapse (1-3 Prior Lines)

Bispecifics and CELMoDs moving into earlier relapse settings:

• Bispecific antibodies:
  • NCT05552222 - Teclistamab + daratumumab + lenalidomide (Tec-DR) vs standard in 1-3 prior lines (Phase 3)
  • NCT05243797 - Teclistamab + lenalidomide vs teclistamab alone in relapsed myeloma (Phase 3)
  • NCT06932562 - Linvoseltamab vs standard in relapsed/refractory myeloma (Phase 3)
  • NCT07222761 - Linvoseltamab monotherapy vs linvoseltamab + carfilzomib (Phase 3)
• CELMoDs:
  • NCT05519085 - Mezigdomide + bortezomib + dex (MEZIVd) vs pomalidomide + Vd (Phase 3)

Relapsed / Refractory — Later Lines (4+ Prior Lines)

Bispecifics and CAR-T for heavily pretreated patients:

• Bispecific comparisons:
  • NCT07518186 - JNJ-79635322 vs teclistamab in relapsed/refractory myeloma (Phase 3)
  • NCT07258511 - JNJ-79635322 vs anti-BCMA×CD3 bispecific (Phase 3)
  • NCT06615479 - BMS-986393 vs standard regimens in relapsed/refractory (Phase 3)
  • NCT07095452 - Etentamig (GPRC5D bispecific) monotherapy vs standard (Phase 3)
  • NCT06158841 - Etentamig monotherapy vs available regimens (Phase 3)
• CAR-T therapy:
  • NCT06413498 - Anitocabtagene autoleucel vs standard of care (Phase 3)
• Bispecific combinations:
  • NCT06208150 - Talquetamab + pomalidomide vs talquetamab + teclistamab vs elranatamab (Phase 3)
  • NCT07452198 - GR1803 vs daratumumab + pomalidomide + dex (DPd) (Phase 3)

Smoldering Myeloma (High-Risk)

Early intervention before progression to active myeloma:

• • NCT07393282 - Linvoseltamab vs daratumumab in high-risk smoldering myeloma (Phase 3)

Maintenance / Consolidation

• • NCT06918002 - Elranatamab/lenalidomide consolidation vs standard maintenance (Phase 3)
  • NCT05020236 - Elranatamab alone and with daratumumab in maintenance (Phase 3)

Showing selected notable trials. View all 564 recruiting interventional trials on ClinicalTrials.gov.

Frequently Asked Questions